NCT05870566 Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]
| NCT ID | NCT05870566 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Claus Cursiefen |
| Condition | Corneal Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2023-11-20 |
| Primary Completion | 2027-09-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The trial evaluates the effect of corneal crosslinking as pre-treatment before corneal transplantation. The goal is to improve graft survival by reducing pathological vessels through pre-treatment.
Eligibility Criteria
Inclusion Criteria: Medical condition or disease to be investigated: \- Pathologically prevascularized cornea with need for corneal transplantation Further inclusion criteria: * Written informed consent by subject and/or witness prior to any study-related procedures * Adult male and female subjects ≥ 18 years old * ≥ 2 corneal quadrants covered by pathological corneal neovascularization * Absence of other clinical contraindications to any part or product of the treatment plan * A cooperative attitude to follow up the study procedures * In case of bilateral disease only one eye will be included * Steroid responders with adequate control regiment or local/systemic therapy can be included Exclusion Criteria: * \< 2 corneal quadrants covered by pathological neovascularization * Corneal stromal thickness below 400 μm (except in the central 8 mm zone which will be replaced later by a new corneal transplant with new endothelium); peripheral stromal thinning below 400 μm in weakened recipient